Følg pressemeldinger fra Aqua Bio Technology ASA
Registrer deg med din epostadresse for å få de nyeste sakene fra Aqua Bio Technology ASA på epost fortløpende. Du kan melde deg av når som helst.
Espen KvaleCEO
Tel:+47 916 28 092espen.kvale@aquabiotech.noAqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.
- Aqua Bio Technology ASA
- Fornebuveien 37
- N-1366 Lysaker
Børsmeldinger
140
MenyAQUA BIO TECHNOLOGY ASA - CORRECTION: Q1 MARKET UPDATE AND UPDATED FINANCIAL CALENDAR25.4.2024 21:18:52 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Aqua Bio Technology ASA ("ABT", and together with its subsidiaries, the "Group") has, as of the first quarter of 2024, achieved NOK 35 million in gross revenues on a consolidated basis with a positive EBITDA. The Group subsidiary, Cover Brands AS, was consolidated into the Group's financial accounts from 1 January 2024. On 12 April 2024, ABT completed the acquisition of Ovalen AS, which will be consolidated into the Group's financial accounts with effect from 1 May 2024. The Group's revenues for the first quarter of 2024 has not been audited. Considering that Q1 is typically the weakest quarter in this segment, with 60% of annual turnover normally occurring in Q3 and Q4, ABT is on track with its previous guidance for a turnover of NOK 140-150 million in 2024. With the integration of Ovalen AS (www.pusteromhudpleie.no) starting from Q2, and assuming satisfactory due diligence and the completion of the acquisition of 3D Innovation Nordic AS and its affiliated companies in Q2, ABT anticip
1 vedlegg
AQUA BIO TECHNOLOGY ASA: Q1 MARKET UPDATE AND UPDATED FINANCIAL CALENDAR25.4.2024 21:05:54 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Aqua Bio Technology ASA ("ABT", and together with its subsidiaries, the "Group") has, as of the first quarter of 2024, achieved NOK 35 million in gross revenues on a consolidated basis with a positive EBITDA. The Group subsidiary, Cover Brands AS, was consolidated into the Group's financial accounts from 1 January 2024. On 12 April 2024, ABT completed the acquisition of Ovalen AS, which will be consolidated into the Group's financial accounts with effect from 1 May 2024. The Group's revenues for the first quarter of 2024 has not been audited. Considering that Q1 is typically the weakest quarter in this segment, with 60% of annual turnover normally occurring in Q3 and Q4, ABT is on track with its previous guidance for a turnover of NOK 140-150 million in 2024. With the integration of Ovalen AS (www.pusteromhudpleie.no) starting from Q2, and assuming satisfactory due diligence and the completion of the acquisition of 3D Innovation Nordic AS and its affiliated companies in Q2, ABT anticip
1 vedlegg
Aqua Bio Technology ASA: Acquisition of 3D Innovation Nordic AS and affiliated companies, together a potential major wholesale group in the Nordics25.4.2024 15:34:41 CEST | Aqua Bio Technology ASA | Inside information
Aqua Bio Technology ("ABT" or the "Company" and together with its wholly owned subsidiaries, the "ABT Group") has today, on 25 April 2024, entered into an agreement (the "Agreement") with CoC Invest AS ("CoC Invest") regarding the Company's acquisition of all of the outstanding shares in the 3D Innovation Nordic AS ("3D"). Pursuant to the Agreement, the Company shall further acquire all of the outstanding shares in the companies Printprofil AS and Check Please AS (jointly with 3D, the "Target Group") from CoC Invest in connection with the acquisition of 3D (jointly, the "Acquisitions"). The Target Group represents a major wholesale group in the Nordics. In 2023, the Target Group had an unaudited turnover of NOK 87.6 million, of which 3D had a turnover of NOK 73 million. The Target Group companies are profitable and EBIDTA for the Target Group in 2023 ended jointly at NOK 5 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board
2 vedlegg
AQUA BIO TECHNOLOGY ASA – DISCLOSURE OF LARGE SHAREHOLDING23.4.2024 16:47:15 CEST | Aqua Bio Technology ASA | Major shareholding notifications
Reference is made to the stock exchange notices from Aqua Bio Technology ASA (the "Company" or "ABT") on 23 April 2024 regarding the amendment agreement ("Amendment Agreement") the Company entered into with Varming Holding AS ("Varming"), and the issuance of 4,708,935 new shares (the "New Shares"), each at a subscription price of NOK 8.20 per new Share, to settle the share element in accordance with the Amendment Agreement. The New Shares has today been resolved by the Company's board of directors pursuant to a board authorization registered in the Norwegian Register of Business Enterprises on 28 September 2023. The New Shares will be delivered to a separate ISIN pending the Company's publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. Following Varming's subscription of the New Shares, Varming and close associates will own a total of 4,976,704 shares and votes in the Company, representing approximately 8.49% of the outstanding votes and
1 vedlegg
Aqua Bio Technology ASA: Cosmed Buyout23.4.2024 12:23:02 CEST | Aqua Bio Technology ASA | Inside information
Pursuant to the agreement Aqua Bio Technology ASA ("ABT" or the "Company") entered with Varming Holding AS as seller ("Varming") with respect to the Company's acquisition of all of the shares in Cosmed Beauty AS ("Cosmed") and Ultrabody AB on 28 June 2022 (the "Agreement"), the purchase price was agreed to be an earn-out based on a multiple of Cosmed's result before tax for each of the financial years ended 2022, 2023, 2024 and 2025. The Company's board of directors regards such earn-out structure as suboptimal and potentially entails a conflict of interests. As such, the Company has today entered into an amendment agreement ("Amendment Agreement") with Varming pursuant to which the Company and Varming settle the remaining earn-out under the Agreement by way of a cash payment of approximately NOK 8.3 million, to be paid by the Company within the end of Q1 2025 and the issuance of 4,708,935 new shares ("New Shares"), each New Share with a subscription price of NOK 8.20. The New Shares a
1 vedlegg
Aqua Bio Technology ASA: Acquisition of Ovalen completed12.4.2024 09:05:41 CEST | Aqua Bio Technology ASA | Inside information
Reference is made to Aqua Bio Technology ASA's ("ABT" or the "Company") stock exchange announcement made 8 February 2024 concerning the Company's intended acquisition of Ovalen AS ("Ovalen") (the "Acquisition"). The Acquisition was subject to a successful due diligence which was completed to ABT's satisfaction and ABT's board of directors has approved the transaction which will be completed on the terms initially agreed. Ovalen had operating revenues of NOK 17 million with an EBITA of NOK 1.1 million in 2023. The purchase price ranges from NOK 6 million to NOK 11 million, where NOK 5 million is contingent upon future revenue and EBIT performance of the Company in 2024 and 2025. NOK 6 million of the purchase price will be settled through the issuance of 1,200,000 consideration shares (the "Consideration Shares") at a subscription price of NOK 5 per Consideration Share. The sellers of Ovalen, including its ultimate beneficial owners, have agreed to a three-year lock-up on the Considerati
1 vedlegg
Aqua Bio technology ASA – share capital increase registered11.3.2024 15:18:15 CET | Aqua Bio Technology ASA | Total number of voting rights and capital
Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 30 January 2024 regarding the Company's board of directors resolving to issue 2,565,717 new shares in the Company in connection with, inter alia, a private placement in the Company ("New Shares"). The New Shares will be delivered on a separate ISIN pending publication of an EEA listing prospectus approved by the Norwegian Financial Supervisory Authority. The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Registry of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 146,450,845 divided into 58,580,338 shares, each with a nominal value of NOK 2.50. For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941 32 288. * * * Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are
1 vedlegg
AQUA BIO TECHNOLOGY ASA – SHARE CAPITAL INCREASE REGISTERED4.3.2024 12:29:48 CET | Aqua Bio Technology ASA | Total number of voting rights and capital
Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 12 February 2024 regarding the Company's board of directors resolving to issue 780,142 new shares in a subsequent offering (the "New Shares"). The share capital increase pertaining to the issuance of the New Shares has today been registered with the Norwegian Registry of Business Enterprises (Nw. Foretaksregisteret). ABT's new share capital is NOK 140,036,552.50 divided into 56,014,621 shares, each with a nominal value of NOK 2.50. * * * For further information, please contact CEO Håvard Lindstrøm mobile phone +47 941 32 288. Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards cons
1 vedlegg
AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING12.2.2024 09:06:28 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company" or "ABT") on 5 February 2024 regarding the key terms for a subsequent offering of up to NOK 5,000,000 through issuance of up to 1,000,000 new shares ("Offer Shares") in the Company at a subscription price of NOK 5 per share (the "Subsequent Offering"). In the Subsequent Offering, the shareholders of the Company as of 30 January 2024 (as registered in the VPS on 1 February 2024), except: (i) shareholders that subscribed for shares in the private placement placed on 30 January 2024, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or would require any prospectus filing, registration or similar action (the "Eligible Shareholders"), received subscription rights giving preferential rights to subscribe for and be allocated Offer Shares in the Subsequent Offering. In addition, certain groups of investors, as described in the stock exchange notice dated 5 Febr
1 vedlegg
Aqua Bio Technology ASA: ABT enter into agreement for the acquisition of Ovalen8.2.2024 21:18:50 CET | Aqua Bio Technology ASA | Inside information
Reference is made to the stock exchange announcement by Aqua Bio Technology ASA ("ABT" or the "Company") on 19 December 2023 where the Company, in connection with the acquisition of Cover Brands, informed that ABT would be given an option to acquire all shares in Ovalen AS ("Ovalen"). In 2022 Ovalen opened a flagship store in central Kristiansand in cooperation with Cover Brands, where the flagship store combines Pusterom Hudpleie's offering of comprehensive beauty experiences and treatments to consumers with attractive products offerings. The Company has today agreed to acquire Ovalen from Coc Invest AS, a company owned by Rolf Kristian Fiala, Ørjan Djuvik Pedersen and Jesper Dønnestad Brandt (the "Ultimate Owners") (the "Acquisition") for a purchase price of up to MNOK 11, where MNOK 5 of the purchase price will be conditional upon Ovalen's revenue and EBIT in 2024 and 2025. Ovalen's revenue in 2023 will be appr. MNOK 17 with a positive EBIT. The purchase price will be converted into
1 vedlegg
Aqua Bio Technology ASA: Subsequent Offering – Further information and start of subscription period5.2.2024 07:38:04 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN Reference is made to the stock exchange announcements by Aqua Bio Technology ASA ("ABT" or the "Company") on 30 and 31 January 2024 regarding the completion of a private placement that raised approximately NOK 12.46 million in gross proceeds (the "Private Placement") and a subsequent offering of new shares in the Company (the "Subsequent Offering"). The Subsequent Offering consists of an offering of up to 1,000,000 new shares in the Company (the "Offer Shares") directed towards the shareholders of the Company as of 30 January 2024 (as registered in the VPS on 1 February 2024) (the "Record Date"), except; (i) shareholders that subscribed for sha
3 vedlegg
Aqua Bio Technology ASA: Terms of the Subsequent Offering31.1.2024 16:04:10 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the stock exchange announcements by Aqua Bio Technology ASA ("ABTEC" or the "Company") on 29 and 30 January 2024 regarding the Private Placement and the contemplated Subsequent Offering as described therein. The Subsequent Offering consists of an offering of up to 1,000,000 new shares in the Company (the "Offer Shares") directed towards the shareholders of the Company as of 30 January 2024 (as registered in the VPS on 1 February 2024) (the "Record Date"), except; (i) shareholders that subscribed for shares in the Private Placement, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful, or would require any prospectus filing, registration or similar action (the "Eligible Shareholders"). In addition, the following types of investors shall have a secondary right to subscribe for the Offer Shares; (i) ABTEC shareholders and investors that participated in the Private Placement, (ii), and (iii) other subscribers without Subscripti
1 vedlegg
AQUA BIO TECHNOLOGY ASA – MANDATORY NOTIFICATION OF TRADES AND DISCLOSURE OF LARGE SHAREHOLDING30.1.2024 17:17:34 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the stock exchange notices from Aqua Bio Technology ASA (the "Company") on 30 January 2024 regarding the completion of a private placement raising gross proceeds of approximately NOK 12.46 million. The following close associates of primary insiders and primary insiders of the Company have been allocated shares in the private placement: RH Industri AS, a close associate of board member Roger Hofseth, has been allocated 300,000 shares; Swelandia International AB, a close associate of board member Jan Petterson, has been allocated 50,000 shares; and Per Egil Borge, chairman of wholly owned subsidiary of the Company Skinteam Norge AS, has been allocated 78,000 shares. Please see the attached forms in accordance with article 19 of the Market Abuse Regulation. Viddas AS has been allocated a total of 1,000,000 shares in the private placement. Following completion of the private placement, Viddas AS and close associates will own a total of 3,073,945 shares in the Company,
4 vedlegg
AQUA BIO TECHNOLOGY ASA: KEY INFORMATION RELATING TO THE SUBSEQUENT OFFERING30.1.2024 10:34:32 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the announcement by Aqua Bio Technology ASA on 30 January 2024 concerning, among other things, a private placement with total gross proceeds of approximately NOK 12.46 million and a contemplated subsequent offering (the "Subsequent Offering"). Date on which the terms of the Subsequent Offering was announced: 29 January 2024 Last day including right: 30 January 2024 First day excluding right: 31 January 2024 Record date: 1 February 2024 Resolution date: 30 January 2024 Maximum number of new shares: 1,000,000 Subscription price: NOK 5 Shall the rights be listed No The formal resolution related to the Subsequent Offering will be made by the board of directors at a later time, and further information will be given in due course. This information is published in accordance with the requirements of the Continuing Obligations.
1 vedlegg
AQUA BIO TECHNOLOGY ASA – CORRECTION: PRIVATE PLACEMENT COMPLETED30.1.2024 10:24:55 CET | Aqua Bio Technology ASA | Inside information
Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company") on 29 January 2024 regarding a contemplated private placement (the "Private Placement") at a fixed subscription price of NOK 5 per new share (the "New Shares") towards certain existing shareholders and certain new investors. The net proceeds of the Private Placement will be used for general corporate purposes, including to fund the Company's growth and to further commercialize the Company's products. The Company received pre-commitments from certain of the Company's largest shareholders, including Viddas AS, RH Industri AS and Initia AB, the two latter being close associates of Board members Roger Hofseth and Jan Petterson, respectively, to subscribe for New Shares equivalent to a subscription amount of NOK 9.4 million. Additionally, Øystein Tvenge pre-committed to subscribe for New Shares for NOK 3 million. The application period in the Private Placement ended today on 30 January 2024 at 08:00 CE
1 vedlegg
AQUA BIO TECHNOLOGY ASA – PRIVATE PLACEMENT SUCESSFULLY PLACED30.1.2024 10:14:54 CET | Aqua Bio Technology ASA | Inside information
Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "Company") on 29 January 2024 regarding a contemplated private placement (the "Private Placement") at a fixed subscription price of NOK 5 per new share (the "New Shares") towards certain existing shareholders and certain new investors. The net proceeds of the Private Placement will be used for general corporate purposes, including to fund the Company's growth and to further commercialize the Company's products. The Company received pre-commitments from certain of the Company's largest shareholders, including Viddas AS, RH Industri AS and Initia AB, the two latter being close associates of Board members Roger Hofseth and Jan Petterson, respectively, to subscribe for New Shares equivalent to a subscription amount of NOK 9.4 million. Additionally, Øystein Tvenge pre-committed to subscribe for New Shares for NOK 3 million. The application period in the Private Placement ended today on 30 January 2024 at 08:00 CE
1 vedlegg
Aqua Bio Technology asa – contemplated Private placement29.1.2024 20:54:00 CET | Aqua Bio Technology ASA | Inside information
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO THE United States, Canada, Australia, Japan or Hong Kong OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Aqua Bio Technology asa – contemplated Private placement Aqua Bio Technology ("ABT" or the "Company") is contemplating an equity offering for gross proceeds of from NOK 10 million to NOK 15 million through issuance new shares (the "Private Placement") (the "New Shares") towards certain existing shareholders and other external investors at a fixed subscription price of NOK 5. The Company may, in its own discretion, increase the maximum size of the Private Placement. The net proceeds of the Private Placement will be used for general corporate purposes, including to fund the Company's growth and to further commercialize the Company'
3 vedlegg
Aqua Bio Technology ASA: Group consolidation completed – Changes in financial reporting24.1.2024 17:15:33 CET | Aqua Bio Technology ASA | Non-regulatory press releases
Aqua Bio Technology ASA ("ABT" and together with its subsidiaries, the "Group") has received consolidated gross revenues year to date of approx. 20 MNOK following the consolidation of its new subsidiary Coverbrands AS in the Group's financial accounts. The Group's consolidated gross revenue for January was higher than expected and increases the likelihood that the Group will deliver the estimated gross revenues of 140-150 MNOK in 2024. Changes in financial reporting to the market: Due to the Group's increased activity ABT will start with quarterly reports to the market from end of Q1 2024 and an updated financial calendar will be issued. Strategy going forward: Further developing ABT while establishing new agreements with third-party distributors in the Nordics and the global market and assessing consolidation opportunities in the Nordic cosmetic market as further highlighted below. Consolidation opportunities in the Nordic cosmetic market: Production and distribution of skincare produ
1 vedlegg
AQUA BIO TECHNOLOGY ASA – SHARE CAPITAL INCREASE REGISTERED10.1.2024 11:07:42 CET | Aqua Bio Technology ASA | Total number of voting rights and capital
Reference is made to the stock exchange announcement from Aqua Bio Technology ASA ("ABT" or the "Company") on 22 December 2023 regarding the completion of the acquisition of Cover Brands AS and the pre-committed NOK 5 million investment made by Jesper Dønnestad Brandt and an associated investor (jointly, the "Transactions"). Following the registration of the share capital increases entailed by the Transactions in the Norwegian Registry for Business Enterprises, the Company's share capital is NOK 138,086,197.50 divided into 55,234,479 shares, each with a nominal value of NOK 2.50. * * * For further information, please contact CEO Håvard Lindstrøm mobile phone +47 941 32 288. Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare pr
1 vedlegg
Aqua Bio Technology ASA: Market update January 20245.1.2024 13:39:27 CET | Aqua Bio Technology ASA | Non-regulatory press releases
Aqua Bio Technology ASA ("ABT" and together with its subsidiaries, the "Group") has as of 31 December 2023 achieved approximately NOK 20 million in gross revenues on a consolidated basis, representing a substantial revenue increase compared to the Group's revenues as of 31 December 2022. The Group's new subsidiary Skinteam Norge AS was consolidated in the Group's financial accounts with effect from 1 September 2023. On 22 December 2023, ABT acquired all shares in Cover Brands AS ("Coverbrands") which will be consolidated in the Group's financial accounts with effect from 1 January 2024. The Group's revenues as of 31 December 2023 have not yet been audited. ABT's updated forward-looking statement for 2024 is as follows: - Estimated gross income in 2024 for ABT is approximately 140–150 MNOK with an estimated gross margin of approximately 50%. Strategy going forward: Further developing ABT while establishing new agreements with third-party distributors in the Nordics and the global market
1 vedlegg
- 1
- 2
- 3
- 4
- 5
- Siste
- >>
Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.
- Aqua Bio Technology ASA
- Fornebuveien 37
- N-1366 Lysaker